

## Poster Session III – Wednesday



Advocacy Affiliate - International Mental Health Resource Organization  
“IMHRO Rising Star Awards”

Cindy Dyar, Brandon Staglin

1. Membership Advisory Task Force: Feedback, Challenges, and Solutions in 2012

Katherine E. Burdick, Linda Carpenter, Marlene Freeman, Vaishali Bakshi, Paul Holtzheimer, Lisa Monteggia, Thomas Schulze, Carlos Bolanos-Guzman, Kristin Cadenhead, Raymond Cho, Cynthia Crawford, Paul Kenny, Gregory Light, Gonzalo Laje

2. Treatment with Adjunctive Aripiprazole Results in Significant Improvement Compared with Continued Antidepressant Monotherapy in Patients with Mild, Moderate, and Severe Major Depressive Disorder

J. Craig Nelson, Thomas D. Stewart, Ainslie Hatch, Kimberly Largay, Elizabeth E. Bellochio, Sabrina V. Marler, Ross A. Baker, John Sheehan, Robert M. Berman

3. Genomic Predictors of Response to Antidepressant Treatment in Geriatric Depression using Genome-wide Expression Analyses: A Pilot Study

Helen Lavretsky, Ascias Eskin, Stanley Nelson, Steve Cole

4. The Acetylcholinesterase Inhibitor, Rivastigmine, but not Huperzine A, Improves Verbal Learning/Episodic Memory and Working Memory in Cocaine-dependent Volunteers

James Joseph Mahoney, Ari Kalechstein, Thomas Newton, Ryan Bennett, Nicholas Arnoudse, Richard De La Garza

5. Treatment of Depression with Botulinum Toxin A: A Randomized, Double-blind, Placebo Controlled Trial

Eric Finzi, Norman Rosenthal

Poster Session III—Wednesday

6. Adjunctive Aripiprazole More than Doubles the Rate of Early and Sustained Response across Multiple Measures in Patients with MDD who have an Inadequate Response to Antidepressant Monotherapy  
Daniel E. Casey, Kimberly Laubmeier, Eudicone James, Ronald N. Marcus, Ross A. Baker, John Sheehan, Robert M. Berman
7. A Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder  
Carolyn I. Rodriguez, Lawrence S. Kegeles, Amanda Levinson, Sue Marcus, Helen Blair Simpson
8. Safety and Tolerability of Atomoxetine Hydrochloride in a Placebo-controlled Randomized Withdrawal Study in Adults with Attention-Deficit/Hyperactivity Disorder  
Himanshu P. Upadhyaya, Angelo Camporeale, J. Antoni Ramos-Quiroga, David Williams, Yoko Tanaka, Jeannine Lane, Robert R. Conley, Rodrigo Escobar, Paula Trzepacz, Albert J. Allen
9. Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: A Phase III, International, Randomized, Double-blind, Placebo-controlled Trial  
Stephen R. Zukin, John Kane, Andrew J. Cutler, Yao Wang, Oksana Mokliatchouk, Krisztián Nagy, István Laszlovszky, Suresh Durgam
10. Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia  
Robert W. Buchanan, Elaine Weiner, Deanna L. Kelly, Robert P. McMahon, James M. Gold, David Gorelick
11. Effects of Suvorexant, an Orexin Receptor Antagonist, on Next Day Driving Performance in Healthy Volunteers  
Annemiek Vermeeren, Eric Vuurman, Anita Van Oers, Cees Van Leeuwen, Stefan Jongen, An Bautmans, Xiaodong Li, Tara Siringhaus, Ingeborg Heirman, Tine Laethem, Matthew Troyer, David Michelson, Hong Sun

Poster Session III—Wednesday

12. Effects of the Mu-Opioid Receptor Antagonist GSK1521498 on Brain Responses to Food Cues, Hedonic and Consummatory Eating Behaviour and Bodyweight: A Proof of Mechanism Study in Binge Eating Obese Subjects

Pradeep Nathan, Hisham Ziauddeen, Samuel R. Chamberlain, Victoria Cambridge, Mark Bush, Wenli Tao, Annelize Koch, Chris Dodds, Kay Maltby, Andrew Skeggs, Lucy Cheke, Sadaf Farooqi, Stephen O’Rahilly, Paul Fletcher, Edward Bullmore

13. Mindfulness Training Improves Resilience: Reductions in Adrenocorticotrophic Hormone (ACTH) Response to Laboratory Stress

Elizabeth Hoge, T.H. Eric Bui, Christina Metcalf, Mark H. Pollack, Naomi M. Simon

14. A Phase III, Double-blind, Placebo-controlled, Flexible-dose Study of Levomilnacipran SR in Patients With Major Depressive Disorder

Angelo Sambunaris, Anjana Bose, Carl Gommoll, Changzheng Chen, William M. Greenberg, Stephen R. Zukin, David V. Sheehan

15. Relapse Risk after Discontinuation of Risperidone in Alzheimer’s Disease

Davangere P. Devanand, Susan Schultz, Jacobo Mintzer, David Sultzer, Gregory Pelton, Howard Andrews, Danilo de la Pena, Sanjay Gupta, Corbett Schimming, Sylvia Colon, Bruce Levin

16. Predictors of Middle-of-the-night Dosing in Primary Insomnia Subjects (Sleep Maintenance Type) Participating in a 4-Week Outpatient Clinical Trial of 3.5 mg Sublingual Zolpidem Tartrate versus Placebo

Thomas Roth, Wallace Mendelson, Nikhilesh Singh, Frank J. Steinberg, Margaret Moline

**Poster Session III—Wednesday**

17. Partial Adherence to Antipsychotic Treatment and Return of Positive Symptoms in First-episode Schizophrenia Patients

Juan A. Gallego, Delbert G. Robinson, Majnu John, Perihan E. Guvenek-Cokol, Jessica L. Greenberg, John Kane

18. ALKS 5461, a Novel Opioid Receptor Modulator, Reduces the Subjective Effects of Cocaine and was Safe and Well Tolerated during Concurrent Cocaine Administration

Ryan Turncliff, Bernard Silverman, Yangchun Du, Bradley Vince, Edward Sellers, Nancy Chen, Megan Shram, Mark Todtenkopf, Elliot W. Ehrich

19. The Failed CNS Studies Phenomenon: Is the Final Factor Looking Us Right in the Eye?

Charles S. Wilcox, Judy L. Morrissey, Nader Oskooilar, Mellissa M. Henry, Daniel E. Grosz, My-Linh Tong, Don F. De Francisco

20. GLYX-13, an NMDA Receptor Functional Partial Agonist, Reduced Depression Scores without Psychotomimetic Effects in Subjects with Major Depressive Disorder who had Failed Another Antidepressant Agent During the Current Episode

Sheldon Preskorn, Matthew Macaluso, Benji Kurian, Raymond Manning, Vishaal Mehra, Gary Zammit, Joseph Moskal, Jeffrey Burgdorf, Ronald M. Burch

21. Attrition and Retention among African Americans in a Pharmacological Treatment Study of Depression: Insights from the STAR\*D Study

Eleanor Murphy, Layla Kassem, A. John Rush, Gonzalo Laje, Francis J. McMahon

Poster Session III—Wednesday

22. Assessment of Safety, Cardiovascular and Subjective Effects after Intravenous Cocaine and Lofexidine

Richard De La Garza, Gantt Galloway, Thomas Newton, John Mendelson, Colin Haile, Ekaterina Dib, Rollin Hawkins, Chwen-Yuen Chen, James Joseph Mahoney, Jurij Mojsiak, Guifang Lao, Ann Anderson, Roberta Kahn

23. In a 2-Year Placebo-controlled Randomized Trial, Galantamine-treated Patients had Lower Mortality Rates and Slower Decline in Cognition and Activities of Daily Living

Klaus Hager, Alan S. Baseman, John H. Han, Mary Sano, Henry M. Richards

24. Keeping it Real: Dissemination of Clinical Trial Results Using Clinician-friendly Effect Size Measures

Leslie Citrome

25. GIRK Channel Inhibitors Decreased Preference in Mice and Relapse Risk Scores in Alcoholics

Nagisa Sugaya, Yasukazu Ogai, Yuzo Aikawa, Mitsuru Umeno, Yosuke Yumoto, Mihoko Takahama, Miho Tanaka, Yoichi Kakibuchi, Eiichi Senoo, Yukio Takamatsu, Hideko Yamamoto, Yoko Hagino, Athina Markou, Kazutaka Ikeda

26. A Randomized Controlled Trial of Cognitive-behavioral Therapy Versus Risperidone for Augmenting Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder

Helen Blair Simpson, Edna Foa

**Poster Session III—Wednesday**

27. Empirical Development of Depression Subtypes Using Factor Analysis of Subject Self-reports Across Symptom Domains

Marisa Toups, Guanghua Xiao, Yang Xie, Thomas Carmody, Benji Kurian, Madhukar Trivedi

28. Varenicline Attenuates Methamphetamine-induced Subjective Effects in Methamphetamine-dependent Volunteers

Christopher D. Verrico, James Joseph Mahoney, Ryan S. Bennett, Thomas F. Newton, Richard De La Garza

29. A Double-blind, Placebo-controlled, Multicenter trial of Adjunctive Armodafinil in Adults with Major Depression Associated with Bipolar I Disorder

Joseph R. Calabrese, Mark A. Frye, Ronghua Yang, Terence A. Ketter

30. Efficacy and Safety of Lisdexamfetamine Dimesylate in Treatment of Adults with Binge Eating Disorder: A Randomized, Double-blind, Placebo-controlled Trial

Susan McElroy, James Mitchell, Denise Wilfley, Maria Gasior, M. Celeste Ferreira-Cornwell, Joseph Gao, Jiannong Wang, Strakowski Stephen, James Hudson

31. Kynurenic Acid Correlates with Neopterin in Hepatitis C Virus Patients: Implications for the Efficacy and Psychological Side-effects of Interferon-Alpha Treatment

Waldemar Turski, Wojciech Zgrajka, Gregory F. Oxenkrug

32. Functional Connectivity Following GABAergic Challenge: Neural Correlates of Sedation and Intoxication

Stephanie Licata, Lisa Nickerson, Amy Janes, Steven Lowen, George Trksak, Scott Lukas

Poster Session III—Wednesday

33. Genetic Risk of Suicidal Behavior in Bipolar-spectrum Disorder: Analysis of 737 Pedigrees

Mirko Manchia, Tomas Hajek, Claire O'Donovan, Valeria Deiana, Caterina Chillotti, Martina Ruzickova, Maria Del Zompo, Martin Alda

34. Effect of Chronic Haloperidol on Glutamate Metabolism in Rat Cortex

Glenn Konopaske, Alo Basu, Joseph Coyle

35. Synaptic and Mitochondrial Changes in the Anterior Cingulate Cortex in Schizophrenia

Keri A. Barksdale, Joy Roche, Rosalinda C. Roberts, Adrienne C. Lahti

36. Persistently Increased Danger Signaling in the Adult Prefrontal Cortex following Adolescent Intermittent Ethanol is Associated with Reversal Learning Deficits

Ryan P. Vetreno, Liya Qin, Fulton T. Crews

37. Association of Anticipatory Connectivity in Insula with the Clinical Course of Major Depression: A Follow-up fMRI Study

Irina A. Strigo, Elena Kosheleva, Alan A. Simmons

38. Exercise Reduces Cocaine Abuse and Enhances Pharmacotherapy: Sex Differences

Marilyn E. Carroll, Natalie E. Zlebnik, Amy T. Saykao

39. In Vivo Binding of the Dopamine-1 Receptor PET tracers [11C]NNC112 and [11C]SCH23390: A Comparison Study in Individuals with Schizophrenia

Ragy R. Girgis, Eline Poels, Mark Slifstein, Anissa Abi-Dargham

Poster Session III—Wednesday

40. Aripiprazole Once-monthly for the Treatment of Schizophrenia: A Double-blind, Randomized, Non-inferiority Study vs. Oral Aripiprazole

W. Wolfgang Fleischhacker, Raymond Sanchez, Pamela P. Perry, Na Jin, Timothy Peters-Strickland, Brian R. Johnson, Ross A. Baker, Anna Eramo, Robert D. McQuade, William H. Carson, John M. Kane

41. Inflammatory Genes Expression as Biomarkers for Personalised Treatment in Psychiatry

Annamaria Cattaneo, Christoph Anacker, Nilay Hepgul, Mark Horowitz, Valeria Mondelli, Ksenia Musaelyan, Patricia Zunszain, Carmine M. Pariante

42. “Nonlinear Techniques as an Approach to Understand Mood Regulation in Bipolar Disorder”

Abigail Ortiz, Kamil Bradler, Julie Garnham, Claire Slaney, Martin Alda

43. A Re-analysis Using a Population-Enrichment Strategy of a Double-blind, Placebo-controlled Study of Chromium Picolinate in Atypical Depression

Maurizio Fava, Roberto Gomeni, James Komorowski, John Docherty, Cristina Cusin, David Soskin, David Mischoulon

44. Multi-site Validation of Touch Screen-based Translational Assays of Cognition and their Pharmacological Sensitivity

Rouba Kozak, Linda Mulryan, Brian J. Eastwood, Douglas S. Chapin, Theresa Ballard, Gary Gilmour, Francois Gastambide, Sophie Dix, Sanna K. Janhunen, Niels Plath, John Talpos, Laetitia Fellini, Linda Lerdrup, Sophie Billa, Iida Ahokas, Lisa M. Saksida, Eric G. Mohler, Lynne E. Rueter, Nadia Malik, Roger Wyler

Poster Session III—Wednesday

45. Targeting Cortical Oscillations with Non-invasive Brain Stimulation in Computer Simulations and Humans

Kristin Sellers, Mohsin Ali, Michael Boyle, Bradley Vaughn, John Gilmore, Flavio Frohlich

46. Mapping Brain Metabolic Connectivity in Awake Rats with MicroPET and Optogenetic Stimulation

Panayotis Thanos, Lisa Robison, Eric Nestler, Ronald Kim, Mike Michaelides, Mary Kay Lobo, Nora D. Volkow

47. A Brief Monetary Progressive Ratio Task Predicts Clinical Amotivation and Ventral Striatum Activation in Schizophrenia

Jacob Kantrowitz, Natalie Katchmar, Theodore Satterthwaite, Lillie Vandekar, Ruben Gur, Raquel Gur, Daniel Wolf

48. The Relationship between Early Life Stress and Brain Volume in Treatment-seeking Alcoholics

Laura Kwako, Melanie Schwandt, Victoria Brown, Erica N. Grodin, Markus Heilig, Daniel W. Hommer, Vijay Ramchandani

49. Chronic Naltrexone Modulates Marijuana's Reinforcing, Subjective and Cardiovascular Effects

Margaret Haney, Gillinder Bedi, Ziva Cooper

50. Increased Hippocampal Glutamate Correlates with Hippocampal Volumetric Deficits in Unmedicated Patients with Schizophrenia

Nina V. Kraguljac, David M. White, Meredith A. Reid, Jan den Hollander, Adrienne C. Lahti

**Poster Session III—Wednesday**

51. Altered Cortical Activation during Episodic Memory Encoding and Recognition in First-episode Psychosis

Michael M. Francis, Brenna C. McDonald, John D. West, Nikki Mehdiyoun, Tom A. Hummer, Jenifer L. Vohs, Emily Liffick, Andrew J. Saykin, Alan Breier

52. Transitive Inference in Relatives of Schizophrenia Patients

Obiora E. Onwuameze, Beng Ho

53. Regionally Specific Theta, Alpha, and Gamma Resting State Abnormalities in Schizophrenia

Yu-Han Chen, Breannan Howell, J. Christopher Edgar, Mingxiong Huang, Michael Hunter, Emerson Epstein, José Cañive

54. Association between the Change in Electrodermal Activity after Acute Tryptophan Depletion and Mood, Aggression and Venturesomeness in Young People with Attention Deficit Hyperactivity Disorder

Georg von Polier, Caroline Biskup, Wiebke F. Kötting, Sarah Bubenzer, Katrin Helmbold, Albrecht Eisert, Tilman J. Gaber, Florian Daniel Zepf

55. Longer-term Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-resistant Depression

Mauricio Tohen, Elizabeth Brunner, Olawale Osuntokun, John Landry, Rebecca Schroer, Michael Thase

56. Uridine Reduces Symptoms in Adolescent Bipolar Depression: A Phosphorus-31 Magnetic Resonance Spectroscopy Study

Douglas G. Kondo, Xian-Feng Shi, Young-Hoon Sung, Tracy L. Hellem, Rebekah S. Huber, Bethany R. Nickerson, Lauren N. Forrest, Perry F. Renshaw

Poster Session III—Wednesday

57. A Randomized Trial Administering Aspirin, Minocycline or Pramipexole vs Placebo as Add-on to Antipsychotics in Patients with Schizophrenia or Schizoaffective Disorder

Mark Weiser, Shimon Burshtein, Liliana Fodoreanu, Roxana Chiriță, Ghiorghe Talău, Diana Cirjaliu, John M. Davis, Michael Davidson

58. The Value of Risk Reduction in CNS Drug Development: Use of Net Present Value as One Model

Walter Greenblatt, Craig H. Mallinckrodt, Janet B.W. Williams, Danielle Popp, John Kane, Michael J. Detke

59. Personality Traits and Treatment of Major Depressive Episodes Associated with Bipolar I Disorder

Gary S. Sachs, Cynthia Siu, Josephine Cucchiaro, Robert Silva, Fred Grossman, Jay Hsu, Amir Kalali, Antony Loebel

60. Do Short-term Effects of Cholinesterase Inhibitors Predict Long-term Outcomes?

Bonnie Davis, Mary Sano

61. Efficacy of Adjunctive Quetiapine SR in a Randomized, Double-blind, Placebo-controlled Study of Mixed States (MS) in Bipolar Disorder (BD)

Vivek Singh, Charles Bowden

62. Feasibility of Centralized Ratings for Mental Health Safety Screening in a Dermatology Trial

Janet B.W. Williams, Daniel Davis, Danielle Popp, Jason Gross, Donna Salvucci, Michael J. Detke

Poster Session III—Wednesday

63. Imaging Cognition Circuits for Treatment Prediction in Major Depressive Disorder: Results from the International Study to Predict Optimized Treatment in Depression (iSPOT-D)

Anett Gyurak, Mayuresh Korgaonkar, Stuart Grieve, Leanne Williams, Amit Etkin

64. Six-month Depot Naltrexone Treatment Reduces Relapse in Parolees Formerly Addicted to Opioids

James Cornish, Courtney D. Nordeck, Daniel D. Langleben, Donna Coviello, Kevin Lynch, Tamara Boney, Charles P. O'Brien

65. Non-steroidal Anti-inflammatory Drug Use is Associated with Lower Remission Rate with Escitalopram but not with Other Antidepressants

Madhukar Trivedi, Marisa Toups, Thomas Carmody, Benji Kurian, Jennifer Warner-Schmidt, Kimberly E. Vanover, A. John Rush, Paul Greengard

66. Sensory-specific Satiety in Schizophrenia

James A. Waltz, Jaime K. Brown, Thomas J. Ross, Betty J. Salmeron, James M. Gold, Elliot A. Stein

67. Reward Circuitry Function in Euthymic Adults with a History of Major Depressive Disorder

Gabriel S. Dichter, Crystal Schiller, Moria Smoski

68. Oxytocin Influences Response Bias in Men but not Women in a Signal Detection Emotion Perception Task

Naomi M. Simon, Spencer Lynn, Elizabeth Hoge, Laura Fischer, Lisa Feldman Barrett

Poster Session III—Wednesday

69. Deficits in Functional Capacity and Impaired Glycemic Control: Urban African Americans with Type 2 Diabetes

Dominique L. Musselman, Marcia McNutt, David Ziemer, Erica Royster, Philip Harvey

70. Impulsivity in Relation to Emotional Stress in Borderline Personality Disorder

Sylvia Cackowski, Annegret Krause-Utz, Anne-Christine Reitz, Christian Schmahl

71. Neural Mechanisms Associated with Switching Attention from an Internal to an External Focus

Emily R. Stern, Alexandra F. Muratore, Stephan F. Taylor, James L. Abelson, Patrick R. Hof, Wayne K. Goodman

72. Enhancing Self Control of Smoking with Real Time fMRI

Luke Stoeckel, Satra Ghosh, Anisha Keshavan, Julia Stern, Susan Whitfield-Gabrieli, John DE. Gabrieli, A. Eden Evins

73. Lifetime Comorbidity of Obsessive-Compulsive Disorder and Sub-threshold Obsessive-Compulsive Symptomatology in the Community: Impact, Prevalence, Socio-demographic and Clinical Characteristics

Naomi A. Fineberg, Michael Hengartner, Carmel Bergbaum, Tim M. Gale, Kiri Jefferies, Wulf Rössler, Jules Angst

74. Attention and Positive Affect in Bipolar Disorder: An fMRI Study

Thilo Deckersbach, Andrew Corse, Elizabeth Greiter, Amanda Arulpragasam, Navneet Kaur, Tina Chou, Scott Rauch, Andrew A. Nierenberg, Darin Dougherty

Poster Session III—Wednesday

75. Differences in Neural Response to Extinction Recall in Young Adults Characterized as Behaviorally Inhibited/noninhibited during Early Childhood

Tomer Shechner, Nathan Fox, Jaime Mash, Carolyn Spiro, Melanie Hong, Ellen Leibenluft, Daniel S. Pine, Britton Jenifer

76. The Neurosteroids Allopregnanolone and DHEA Enhance Emotion Regulation Neurocircuits and Modulate Memory for Emotional Stimuli

Rebecca K. Sripada, Christine E. Marx, Anthony P. King, Sarah N. Garfinkel, James L. Abelson, Israel Liberzon

77. The Nicotinic Partial Agonist Varenicline Attenuates Visuospatial Working Memory Deficits in Schizophrenia Induced by Cigarette Smoking Abstinence

Victoria C. Wing, Caroline E. Wass, Tony P. George

78. Decision Making and Psychological Pain in Acutely Suicidal Depressed Patients

Ricardo Caceda, Philip Harvey, Dante Durand, Edmi Cortes, Stefania Prendes, Justyna Wojas, Charles Nemeroff

79. The Effects of Cannabis Abstinence on Neurocognitive and Clinical Symptoms in Cannabis Dependent Individuals with and without Schizophrenia

Rachel A. Rabin, Christiana Stefan, Konstantine K. Zakzanis, Tony P. George

80. Conflict Monitoring and Adaptation in Individuals at Familial Risk for Developing Bipolar Disorder

Luis R. Patino Duran, Caleb M. Adler, Neil Mills, Strakowski Stephen, David Fleck, Jeffrey Welge, Melissa DelBello

Poster Session III—Wednesday

81. Theta Power Modulation of Selective Encoding in Schizophrenia  
J Daniel Ragland, Joshua Phillips, Michael Minzenberg, Tyler A. Lesh, Tara Niendam, Marjorie Solomon, Jong Yoon, Cameron Carter, Charan Ranganath
82. Differential Roles of Basic Visual Information in Fear and Happiness Perception in Schizophrenia  
Yue Chen
83. Parents of Low Socioeconomic Status: Brain Function and Structure is Affected by Perceived Social Status and Early Life Experience  
James E. Swain, S. S. Ho, Gary W. Evans, Xin Wang, Robert Varney, Israel Liberzon
84. Olanzapine, but not Fluoxetine, Treatment Increases Survival in Activity-based Anorexia in Mice  
Stephanie C. Dulawa, Stephanie Klenotich, Mariel Seiglie, Matthew McMurray, Jamie Roitman, Daniel Le Grange, Priya Dugad
85. Antipsychotic use, Cardiometabolic health and Care Coordination: Implementation of Metabolic Monitoring Guidelines in a Large Outpatient Psychiatry Clinic  
Jayesh Kamath, Ksenia Nawrocki, Rebecca Andrews
86. Brain GABA in Schizophrenia and Bipolar Disorders  
Juan Bustillo, Hongji Chen, Thomas Jones, Nicholas Lemke, Chris Abbott
87. A Brain-selective Prodrug of 17 $\beta$ -Estradiol in the Male Mouse: Implications for the use of Estrogen in Men who Suffer from Mood and Anxiety Disorders  
Michal Arad, Sean C. Piantadosi, Katalin Tatrai-Prokai, Istvan Merchenthaler, Laszlo Prokai, Todd D. Gould

**Poster Session III—Wednesday**

88. Haste or Speed? Balancing Speed and Accuracy during a Motivated Reaction Time Task in Remitted and Depressed Patients with Bipolar Disorder

Henry W. Chase, Haris Aslam, Jorge Almeida, Mary L. Phillips

89. An Improved Framework for Confound Regression and Filtering for Control of Motion Artifact in the Preprocessing of Resting-State Functional Connectivity Data

Theodore D. Satterthwaite, Mark Elliott, Raphael Gerraty, Kosha Ruparel, James Loughhead, Monica Calkins, Simon Eickhoff, Hakon Hakonarson, Ruben Gur, Raquel Gur, Daniel Wolf

90. Effects of Yoga on Cognition, Psychiatric Symptoms, Weight and Biochemical Changes in Chronic Schizophrenic Patients

Robert C. Smith, Merlyn Mathew, Lawrence Maayan, Patricia L. Gerbarg, Richard Brown, Elizabeth Visceglia, Henry Sershen, Abel Lajtha, Sylvia Boules, James Auta, Alessandro Guidotti, John M. Davis

91. Depression-associated Risk Variant in GRM7 Predicts Vulnerability in Offspring at Risk for Major Depression and is Associated with Cortical Thickness Patterns

Guia Guffanti, Priya Wikramaratne, Ardesheer Talati, Ravi Bansal, Susan E. Hodge, Carolyn Erdman, Virginia Warner, Philips Adams, Marc Gameroff, Zagaa Odgerel, Bradley S. Peterson, Myrna M. Weissman, Steven P. Hamilton

92. Assessments of Everyday Functioning in Schizophrenia

Samir Sabbag, Felicia Gould, Dante Durand, Philip Harvey

Poster Session III—Wednesday

93. Genetic Association between Dopamine Signaling Molecules and Striatal Presynaptic Dopamine

Daniel P. Eisenberg, Joseph C. Masdeu, Philip D. Kohn, Bhaskar S. Kolachana, Daniel R. Weinberger, Karen F. Berman

94. Correlation of Cortisol but not BDNF Levels with Hippocampal Activation in Depressed Patients

Shigeru Toki, Yasumasa Okamoto, Masahiro Takamura, Tomoya Matsumoto, Shinpei Yoshimura, Tetsuya Yamamoto, Shigeto Yamawaki

95. Electroconvulsive Therapy Response in Major Depressive Disorder: A Pilot Functional Network Connectivity Resting State fMRI Investigation

Chris Abbott, Nicholas Lemke, Shruti Gopal, Robert Thoma, Juan Bustillo, Vincent Calhoun, Jessica Turner

96. Methylome Sequencing in the Alcohol Post-dependent Rat Model

Estelle Barbier, Jenica Tapocick, Nathan Jurgens, Jesse R. Schank, Kornel Schuebel, Zhifeng Zhou, Qiaoping Yuan, David Goldman, Markus Heilig

97. Effects of Pharmacogenetic Manipulation of the Nucleus Accumbens on Neuronal Activity and Alcohol Seeking Behaviors

Angela R. Ozburn, Joseph Kern, Kush Purohit, Colleen A. McClung

98. Anhedonia and Neural Response to Social Reward in Adolescents

Erika E. Forbes, Kati Healey, Thomas Olino, Erin Coffman

Poster Session III—Wednesday

99. Characterizing the Splicing Variants of ZNF804a in Human Brain

Ran Tao, Chao Li, Joo Heon Shin, Bin Xie, Yuan Gao, Tianzhang Ye, Andrew Jaffe, Barbara Lipska, Joel E. Kleinman, Daniel R. Weinberger, Thomas M. Hyde

100. Antidepressant Effects of Optogenetic Control of Nucleus Accumbens Neurons

T. Chase Francis, Jeffrey D. Lenz, Eric Finkel, Dipesh Chaudhury, Ming-Hu Han, Mary Kay Lobo

101. Ketamine and Neurocognition in Depression: The Modulating Effects of Lamotrigine

James W. Murrough, Le-Ben Wan, Benjamin Glicksberg, Katherine A. Collins, Sanjay J. Mathew, Dennis S. Charney, Dan V. Iosifescu, Katherine E. Burdick

102. A New Animal Model of the Pathophysiology of Tourette Syndrome: Parallel Characterization of Humans and Mice with a Disruption of the Histidine Decarboxylase (Hdc) Gene

Lissandra Baldan, Kyle Williams, Jean-Dominique Gallezot, Michael Crowley, Vladimir Pogorelov, Roxanne Gorczyca, George Anderson, Bennett Leventhal, Hiroshi Ohtsu, Zoe A. Hughes, John H. Krystal, Linda Mayes, Ivan de Araujo, Yu-Shin Ding, Matthew State, Christopher Pittenger

103. The Effects of Heterozygous Knockout of the Vesicular Monoamine Transporter (VMAT2) and Transgenic Overexpression of Alpha-Synuclein (SYN) on Locomotor Behavior in Mice

Frank S. Hall, Maria Perona, Charles Tsouvalas, Michael Baumann, Eliezer Masliah, George Uhl

Poster Session III—Wednesday

104. Adult Hippocampal Neurogenesis Modulates Excitability of the Dentate Gyrus

Amar Sahay, Taruna Ikrar, Sally Levinson, Antoine Besnard, Alexis Hill, Rene Hen, Xiangmin Xu

105. Neuronal Signatures of Self-control in Anterior Cingulate Cortex

Benjamin Hayden, Tommy Q. Blanchard

106. GLYX-13, an NMDA Receptor Glycine-site Functional Partial Agonist, Induces Rapid Antidepressant-like Effects without Ketamine-like Side Effects

Jeffrey Burgdorf, Xiao-lei Zhang, Katherine Nicholson, Robert Balster, J. David Leander, Patric Stanton, Roger Kroes, Joseph Moskal

107. Chronic Unpredictable Stress Dysregulates Glutamate Neurotransmission, Neuronal Plasticity and Cognitive Flexibility in the Rat Medial Prefrontal Cortex

Julianne Jett, Brian Bingham, David A. Morilak

108. Cognitive Features after Long-term Breast Cancer Survival: Longitudinal Evaluation of Neuropsychological Function into Later Life

Susan Schultz, Christopher M. Nguyen, Natalie L. Denburg, Torricia H. Yamada, Leigh Beglinger

109. Nonconscious Color Priming Reveals Intact Feedforward Visual Processing in Schizophrenia

Jonathan K. Wynn, Carol Jahshan, Bruno Breitmeyer, Michael F. Green

**Poster Session III—Wednesday**

110. Neuropsychological Performance in Phenotypes of Pediatric Bipolar Disorder

Daniel P. Dickstein, David A. Axelson, Shirley Yen, Jeff Hunt, Heather Hower, Mary Kay Gill, Lauren Weinstock, Tina Goldstein, Benjamin Goldstein, Neal Ryan, michael strober, Boris Birmaher, Martin Keller

111. Impaired Reward Responsiveness during Nicotine withdrawal in Rats and Humans Assessed in a Translational Behavioral Procedure

Andre Der-Avakian, Michele L. Pergadia, Manoranjan S. D'Souza, Pamela AF. Madden, Andrew C. Heath, Saul Shiffman, Diego A. Pizzagalli, Athina Markou

112. Loss Aversion with Respect to Prospect Theory and Relative Preference Theory

Sang Lee, Myoung Joo Lee, Jodi M. Gilman, Byoungwoo Kim, John Kuster, Anne Blood, Hans C. Breiter

113. Probabilistic Reinforcement Learning in Young Adults with Autism Spectrum Disorders Reflects Cognitive Control Deficits

Marjorie Solomon, Michael J. Frank, Anne Smith, J Daniel Ragland, Jong Yoon, Tara Niendam, Tyler A. Lesh, Cameron Carter

114. Respective Contributions of Alcoholism and Bipolar Disorder to Neurocognitive Deficits in Adults with Co-occurring Bipolar Disorder and Alcohol Dependence: Impact of Abstinence

Bryan K. Tolliver, James J. Prisciandaro, Delisa G. Brown, Kathleen T. Brady

Poster Session III—Wednesday

115. Does Targeted Social Cognitive Training Enhance Cortical and Subcortical Activation in Schizophrenia during Reward Processing?

Sophia Vinogradov, Karuna Subramaniam, Srikantan Nagarajan,  
Christine Hooker

116. Catechol-O-Methyltransferase (COMT) Genotype as a Predictor of Response to Computerized Cognitive Remediation in Schizophrenia and Schizoaffective Disorders

Jean-Pierre Lindenmayer, Herbert Lachman, Susan McGurk,  
Saurabh Kaushik, Anzalee Khan-Rhodes

117. Multimodal Neuroimaging of Networks Associated with Working Memory Performance

Katherine H. Karlsgodt, Gerhard Hellemann, Jeanette Mumford,  
Eliza Congdon, Catherine A. Sugar, Angelica Bato, Fred Sabb,  
Edythe London, Russell Poldrack, Robert M. Bilder, Tyrone Cannon

118. Low Frequency Neural Oscillations Associated with Age and Processing Speed in Early- and Adult-onset Schizophrenia

Peter Bachman, Zachary D. Moran, Maria Jalbrzikowski, David C.  
Glahn, Tyrone Cannon, Carrie Bearden

119. Relationship between Anxiety and Vascular Function in Older Individuals with and without Atherosclerotic Vascular Disease

Ashley N. Stillman, David J. Moser, Jess Fiedorowicz, Heather M.  
Robinson, Peggy C. Nopoulos, William G. Haynes

120. Expectation and Hedonics Activate Specific Neural Networks during Reward

Arielle D. Stanford, Sarah Lisanby, Dolores Malaspina, Yael M.  
Cycowicz

Poster Session III—Wednesday

121. Inhibitory Control Deficits in Autism Spectrum Disorders (ASD)

Matthew W. Mosconi, Michael E. Ragozzino, Lauren Schmitt,  
Edwin H. Cook, John Sweeney

122. Violation of Temporal Expectancy Triggers Liability of Amygdala-dependent Memories

Lorenzo Diaz-Mataix, Raquel Martinez, Glenn Schafe, Joseph LeDoux, Doyere Valerie

123. Fine-grained Working Memory Load Manipulation Reveals Absence of Normative Inverted-U Activation in Schizophrenia

Jared X. Van Snellenberg, Ragy R. Girgis, Christina Read, Judy L. Thompson, Jochen Weber, Tor D. Wager, Mark Slifstein, Jeffrey A. Lieberman, Anissa Abi-Dargham, Edward E. Smith

124. If I do it, it Must be Important: An Inhibition Deficit Model of Obsessive Compulsive Disorder

Gideon E. Anholt, Omer Linkovski, Eyal Kalanthroff, Avishai Henik

125. Selective Manipulation of Striatal Circuitry with Serotonin-6 Receptors: Pathway Specific Targeting of 5-HT<sub>6</sub> Receptor Overexpression has Opposing Effects on Behavioral Acquisition and Expression of Habits

Daniel Eskenazi, John F. Neumaier

126. A Novel Task Probing Neural Substrates of Approach-avoidance Conflict: Implications for Understanding Anxiety Disorders

Robin L. Aupperle, Sarah Sullivan, Andrew Melrose, Martin Paulus, Murray B. Stein

Poster Session III—Wednesday

127. Relationship between Plasma Peptide YY and Cardiometabolic Disease Risk Factors in a Cohort of Older Psychiatric Patients

Pei-an Betty Shih, Hua Jin, Sunder Mudaliar, Robert R. Henry, Dilip V. Jeste

128. The Influence of the Brain-derived Nuerotrophic Factor Val66Met Genotype and HMG-CoA Reductase Inhibitors on Insulin Resistance in the Schizophrenia and Bipolar Populations

Kyle Burghardt, Rodica Pop-Busui, Michael Bly, Tyler Grove, Stephan Taylor, Vicki Ellingrod

129. Relationship between Reactivity to Heroin-related Cues, Craving, and Self-administration in Buprenorphine-maintained Heroin Abusers

Sandra D. Comer, Adam Bisaga, Jermaine Jones, Shanthi Mogali, Jeanne Manubay, Maria Sullivan, Suzanne Vosburg, Ziva Cooper, Perrine Roux, Jessica Fogel, Laura Shiffrin

130. Combined Effects of Antipsychotic Medication and Hypoglycemia upon Microglial Activation

Neil M. Richtand, Amanda Isom, Rebecca Ahlbrand, Gary A. Gudelsky

131. Substance use during Cannabis Withdrawal in People with Schizophrenia

Maju Koola, Douglas Boggs, Deanna L. Kelly, Fang Liu, Jared Linthicum, Hailey Turner, Robert P. McMahon, David Gorelick

132. Familial Internalizing and Externalizing Liability Factors Contribute to Borderline Personality Disorder

James Hudson, Mary Zananini, Karen Mitchell, Lois Choi-Kain, Ming Tsuang, John Gunderson

Poster Session III—Wednesday

133. Depression Symptoms Associated with Cannabis Dependence in an Adolescent American Indian Community Sample

David Gilder, Cindy L. Ehlers

134. Mental Disorders in Adolescence and Young Adulthood: Homotypic and Heterotypic Longitudinal Associations

Katja Beesdo-Baum, Daniel S. Pine, Roselind Lieb, Hans-Ulrich Wittchen

135. Migraine Comorbidity Worsens Course of Illness in a Longitudinal Study of Bipolar Disorder

Erika FH. Saunders, Masoud Kamali, Alan J. Gelenberg, Melvin McInnis

136. Childhood Sexual and Emotional Abuse Related to Multiple Unfavorable Bipolar Disorder Illness Characteristics

Shefali Miller, Soumya Parameshwaran, Farnaz Hooshmand, Po Wang, Terence A. Ketter

137. PTSD is Associated with an Increased Prevalence of Autoimmune Disorders

Aoife O'Donovan, Beth Cohen, Daniel Bertenthal, Mary Margaretten, Karen Seal, Thomas Neylan

138. Metabolic Syndrome and Outcomes in Individuals with Bipolar II Disorder

Holly Swartz, Andrea Fagiolini, Paola Rucci, Ellen Frank, David J. Kupfer

Poster Session III—Wednesday

139. Juvenile Antioxidant Treatment Prevents Behavioral and Prefrontal Cortical Deficits in a Developmental Model of Schizophrenia

Danielle S. Counotte, Harry J. Cabungcal, Patrick Piantadosi, Elyse Sullivan, Eastman Lewis, Gwendolyn G. Calhoun, Hugo Tejada, Michel Cuenod, Kim Q. Do, Patricio O'Donnell

140. RNA Editing of an AMPA Receptor Subunit is Altered in Major Depression and Suicide

Monsheel Sodhi, Daniel Mount, Thomas M. Hyde, Joel E. Kleinman

141. Higher Insula Connectivity in Abstinent Stimulant Users

Jazmin Camchong, Sheila Specker, Valerie Slaymaker, Bryon Mueller, Angus MacDonald, Kelvin O. Lim

142. Schizophrenia Subtypes: Going, Going, Gone

David L. Braff, Anthony J. Rissling, Stacy Langton, William Carpenter

143. Seasonality and Diurnal Rhythms of Sleep and Activity assessed by Mobile Technologies in a Community Based Population Study

Adrienne D. Taylor, Femke Lamers, Jihui Zhang, Ruth Benca, Kathleen R. Merikangas

144. Pediatric Bipolar Disorder and Mixed Mood Symptoms: Moderately Prevalent in Community Mental Health and Underdiagnosed by Practitioners

Eric Youngstrom, Jennifer Youngstrom, Guillermo Perez Algorta, Robert L. Findling

**Poster Session III—Wednesday**

145. Clinical Characteristics of Visual Hallucinations in Psychotic Disorders:  
A Cross-sectional Study

Virginie-Anne Chouinard, Dost Ongur, Guy Chouinard, Bruce M. Cohen

146. Risk-taking in Schizophrenia and Controls with and without Cannabis  
Dependence

Bernard A. Fischer, Robert P. McMahon, Deanna L. Kelly, Heidi J. Wehring, Walter Meyer, Stephanie Feldman, William Carpenter, David Gorelick

147. The Influence of Social Setting on Acute Alcohol Effects in Humans

Matthew Kirkpatrick, Harriet de Wit

148. Anatomy of the “Neuropsychiatric Translational Research Revolution:”  
Challenges Abound

David L. Braff, Lara Braff

149. Utilization of Patient-derived Neuronal Cells for Disease Modeling and  
Hypothesis Building in Neuropsychiatric Disease Research

Shinichi Kano, Gustavo Maegawa, Zhifeng Zhou, Ross Cardarelli, Carlo Colantuoni, Qiaoping Yuan, Fang Han, Ashley Wilson, Nicola Cascella, Hongkai Ji, Patricio O'Donnell, David Goldman, Akira Sawa

150. Prepulse Inhibition Detects Evidence of Neurodevelopmental Differences  
in Individuals at Greatest Risk for Psychosis: Findings from the North  
American Prodromal Longitudinal Study (NAPLS)

Kristin Cadenhead, Jean Addington, Tyrone Cannon, Barbara Cornblatt, Daniel H. Mathalon, Thomas McGlashan, Diana Perkins, Larry Seidman, Ming Tsuang

Poster Session III—Wednesday

151. Relationships between Mismatch Negativity, Auditory Emotional Processing, and Psychosocial Functioning in Schizophrenia
- Barbara Breteinstein, Wei-li Chang, Anthony J. Rissling, Richard F. Sharp, Catherine A. Sugar, Ricki-Leigh Malaguti, Marlena Pela, Joyce Sprock, David L. Braff, Gregory A. Light
152. Relationship between Auditory Processing and Affective Prosody in Schizophrenia
- Carol Jahshan, Jonathan K. Wynn, Justina Avila, Michael F. Green
153. Diffusion Tensor Imaging of the Thalamus in Cocaine Dependent Subjects: Association with fMRI and Treatment Response
- F. Gerard Moeller, Khader M. Hasan, Joel Steinberg, Liangsuo Ma, Joy M. Schmitz, Scott Lane, Ponnada A. Narayana
154. Tolcapone Modulates Working Memory Load Related DLPFC Activity and Coupling in Patients with Schizophrenia
- Roberta Rasetti, Venkata S. Mattay, Christopher J. Li, Qiang Chen, Jesse Hochheiser, Joseph H. Callicott, Karen F. Berman, Jose A. Apud, Daniel R. Weinberger
155. Behavioral Economics for Standardized Metrics in CNS Drug Development and Regulation
- Jack E. Henningfield, Steven R. Hursh, Peter G. Roma, Edward J. Cone, August R. Buchhalter, Reginald V. Fant, Sidney H. Scholl
156. The Effect of Stereotype Threat, Perceived Discrimination, and Examiner-examinee Racial Discordance: Simple as Black and White?
- April D. Thames, Robert M. Bilder, Desiree A. Byrd, Charles H. Hinkin, Kimberley Duff

Poster Session III—Wednesday

157. microRNA-206 Regulates Alcohol Consumption and Preference

Jenica Tapocik, Meghan Flanigan, Matthew Solomon, Courtney King, Estelle Barbier, Jesse Schank, Molly Heyer, Paul Kenny, Markus Heilig

158. Developmental Differences in the Neural Correlates of Trial-to-trial Variance in Response Time

Nancy E. Adleman, Richard Reynolds, Gang Chen, Varun Razdan, Daniel S. Pine, Ellen Leibenluft

159. Differentiating Neural Networks with Interleaved TMS-BOLD Imaging: Insight into Addiction

Colleen A. Hanlon, Melanie Canterbury, Joseph Taylor, Truman Brown, Mark S. George

160. The Dopamine D1-D2 Receptor Heteromer Regulates Glycogen Synthase Kinase-3 $\beta$  Activity Independent of Akt in Rodent Prefrontal Cortex: Potential Relevance to Cognitive Function

Melissa L. Perreault, Jace Jones-Tabah, Brian F. O'Dowd, Susan R. George

161. Interleaved TMS/fMRI after rTMS: How to Make the Prefrontal Cortex Sing?

Joseph Taylor, Colleen A. Hanlon, Xingbao Li, Mark S. George

162. Cognitive De-biasing Strategies Significantly Improve the Assessment of Pediatric Bipolar Disorder

Melissa Jenkins, Eric Youngstrom

Poster Session III—Wednesday

163. Economic Evaluation of Antipsychotic Treatment in Pediatric Disruptive Behavior Disorders: An Example from the Metabolic Effects of Antipsychotics in Children (MEAC) Study

Ginger E. Nicol, Josh Edler, Steven M. Kymes, John W. Newcomer

164. Preference for Future Gains and Losses in Patients with Major Depression is Modulated by the Presence of Comorbid Posttraumatic Stress Disorder

Boadie Dunlop, Britta Maciuba, Jan Engelmann

165. Effect of Meta-Chlorophenylpiperazine (mCPP) on Appetite and Satiety and on Emotional Processing and Mood in Healthy Volunteers

Colin T. Dourish, Jason M. Thomas

166. Current Treatment of Obsessive-Compulsive Disorder (OCD): A Cross-Sectional Analysis of OCD Treatment in 9 International Outpatient Settings

Michael Van Ameringen, William Simpson, Beth Patterson

167. Impact of Treatment Approach on Maternal and Neonatal Outcome in Pregnant Opioid-maintained Women

Verena Metz, Reinhold Jagsch, Nina Ebner, Johanna Würzl, Anna Pribasnig, Constantin Aschauer, Gabriele Fischer

168. Discontinuations Following a Switch from Risperidone, Olanzapine, or Aripiprazole to Iloperidone in Patients with Schizophrenia: The i-FANS Study

Leslie Citrome, Farid Kianifard, Xiangyi Meng, Adam Winseck, Marla Hochfeld, Stephen Stahl

**Poster Session III—Wednesday**

169. The Reinforcing and Subjective Effects of Intravenous and Intranasal Buprenorphine in Heroin Users

Jermaine Jones, Sandra D. Comer

170. MDMA Buffers against Cues of Social Rejection

Margaret C. Wardle, Charles G. Frye, Harriet de Wit

171. Neuroprotective Effects of Long-term Lithium Treatment on Amyloid Deposition in Older Adults with Bipolar Disorder

Ariel Gildengers, Julie Price, Butters Meryl, James Becker, Tamer Ibrahim, William Klunk, Charles Reynolds

172. Differences in the Magnitude of BOLD Response to Implicit Emotional Faces Predict Antidepressant Response to Scopolamine in Major Depressive Disorder

Maura L. Furey, Wayne C. Drevets, Ashish Khanna, Carlos A. Zarate

173. ALKS 5461, a Novel Opioid Receptor Modulator, Normalizes Human EEG Responses in an Auditory Oddball Task after Cocaine Administration as Indicated by a Brain Network Activation Analysis

Edward Sellers, Ryan Turncliff, Amit Reches, Dalia Dickman, I Laufer, Keren Ziv, Y Stern, Z Halabi, Bradley Vince

174. Pharmacokinetic Modeling of ALKS 9070 (ALKS 9072), a Novel Once-monthly Prodrug of Aripiprazole

Ryan Turncliff, Wen-i Li, Helen Pentikis

175. Long Acting Injectable vs. Oral Antipsychotics in Schizophrenia: A Systematic Review and Meta-analysis of Mirror-image Studies

Taishiro Kishimoto, Masahiro Nitta, Michael Borenstein, John Kane, Christoph U. Correll

Poster Session III—Wednesday

176. Pharmacokinetic Profile of ITI-007, A Novel Approach for the Treatment of Schizophrenia and Other Psychiatric and Neurological Disorders

Kimberly E. Vanover, Robert E. Davis, Lawrence P. Wennogle, Paul Greengard, Sharon Mates

177. Nicotine Metabolism: Sex Differences in African American and Caucasian Smokers

Andrea King, Lingjiao Zhang, Daniel Roche, Dingcai Cao, Rachel Tyndale

178. Impact on Hospitalization after Initiating Long-acting Injectable Antipsychotics for a Longer vs. Shorter Time Period among Medicaid Insured Patients with Schizophrenia

Rimal Bera, Craig Karson, Steve Offord, Donna Zubek, Gina Lau, Jay Lin

179. Healthcare Impact of Initiating Long-acting Injectable Antipsychotic Therapy among Medicaid Insured Patients with Schizophrenia

Craig Karson, Rimal Bera, Steve Offord, Donna Zubek, Gina Lau, Jay Lin

180. Do Benzodiazepines Really Induce Negative Cognitive Effects in Elderly Psychiatric Patients?

Lars H. Tanum, Gudrun Hoiseth, Marit Tveito, Kari Kristiansen, Kristin Kvande, Bernhard Lorentzen, Helge Refsum, Jorgen Bramness

181. The Efficacy of the Glutamate NMDA Receptor Antagonist Memantine For Cognitive Deficits In Euthymic Subjects with Bipolar Disorder

Dan V. Iosifescu, William S. Gilmer, Alexander Fan, Atilla Gonenc, Constance M. Moore, Christopher Randolph, Mark Hyman. Rapaport, Thilo Deckersbach, Andrew A. Nierenberg

Poster Session III—Wednesday

182. Hydrocortisone and Intrusive Memories in Posttraumatic Stress Disorder

Petra Ludäscher, Christian Schmahl, Martin Bohus

183. Lurasidone Monotherapy for the Treatment of Bipolar Depression: Results of the 6-week, Double-blind, Placebo-controlled PREVAIL-2 Study

Antony Loebel, Josephine Cucchiaro, Robert Silva, Kaushik Sarma, Hans Kroger, Jay Hsu, Joseph R. Calabrese, Gary Sachs

184. Effect of Lurasidone Monotherapy or Adjunctive Therapy on Anxiety Symptoms in Patients with Bipolar I Depression

Robert M.A. Hirschfeld, Josephine Cucchiaro, Andrei Pikalov, Peter Warner, Jay Hsu, Hans Kroger, Antony Loebel

185. Evaluation of Glycine Transporter Inhibitor Org 25935 for the Prevention of Relapse in Alcohol-dependent Patients: A Multisite, Randomized, Double-blind, Placebo-controlled Trial

Armin Szegedi, Andrea deBejczy, Kari Nations, Frank Ruwe, Bo Söderpalm, David Michelson

186. Metabolism and Pharmacokinetics of the Antidepressant Amitifadine in Humans

Randall D. Marshall, Jurgen Venitz, Pierre Tran, David T. Wong, Franklin P. Bymaster

187. The Tryptophan-Kynurenine Pathway in Major Depression: Neuroprotective Effects of Treatment

Angelos Halaris, Aye-Mu Myint, Edwin Meresh, Vidushi Savant, Gilles Guillemin, James Sinacore

Poster Session III—Wednesday

188. Insulin Resistance as a Shared Pathophysiology between Mood and Cardiometabolic Disorders: Relevance of PPAR- $\gamma$  Agonism
- David Kemp, Keming Gao, Timothy Warneka, Carla Conroy, Stephen Ganocy, Famarz Ismail-Beigi, Joseph R. Calabrese
189. The Space of Common Psychiatric Disorders
- Carlos Blanco, Robert Krueger, Deborah Hasin, Shuai Wang, Mark Olfson
190. Levomilnacipran SR 40 mg and 80 mg in Major Depressive Disorder: A Phase III, Randomized, Double-blind, Fixed-dose, Placebo-controlled Study
- David Bakish, Carl Gommoll, Changzheng Chen, William M. Greenberg, Rene Nunez, Michael Liebowitz, Arif Khan
191. The Efficacy of Vilazodone on Anxiety Symptoms in Patients with Major Depressive Disorder: A Post Hoc Analysis of Two Randomized Controlled Trials
- Michael Thase, John Edwards, Dalei Chen, Adam Ruth
192. Predictive Deficits Underlie Auditory Verbal Hallucinations in Schizophrenia: A Model-based fMRI Study
- Guillermo Horga, Kelly Schatz, Anissa Abi-Dargham, Bradley S. Peterson
193. Effect of Paternal Age on Schizophrenia-related Endophenotypes: Examination of Data from the Consortuim on the Genetics of Schizophrenia (COGS)
- Allen David. Radant, Steve Millard, Debby Tsuang, Michelle Esterberg, David L. Braff, Neal R. Swerdlow, Michael F. Green, Keith H Nuechterlein, Larry Siever, Jeremy M Silverman, Bruce I Turetsky, Laura Lazzeroni, Monica Calkins, Larry Seidman, Ann Olincy

Poster Session III—Wednesday

194. Brain Structural Community Abnormalities Revealed using PLACE (Path Length Associated Community Estimation)

Alex D. Leow, Johnson Jonaris GadElkarim, Olusola Ajilore, Liang Zhan, Jamie Feusner, Teena Moody, Paul Thompson, Anand Kumar, Lori Altshuler

195. Testing Glutamatergic Strategies in Early Psychosis: Longitudinal Rodent Pharmacological MRI Studies and a Randomized, Double-blind, Placebo-controlled Proof-of-concept Trial in Patients at Clinical Risk for Psychosis

Scott A. Schobel, Nashid Chaudhury, Usman Khan, Martin Styner, Beatriz Paniagua, Cheryl M. Corcoran, Jeffrey A. Lieberman, Holly Moore, Scott A. Small

196. Transient Ziprasidone's Dopamine D2/3 Receptor Occupancy - A Clinical 24-hour [11C]- Raclopride PET Study

Ariel Graff, Takefumi Suzuki, Hiroyuki Uchida, Gary Remington, Fernando Caravaggio, Carol Borlido, Bruce Pollock, Benoit Mulsant, Vincenzo DeLuca, Zahinoor Ismail, David Mamo

197. Modafinil Modulates Activation and Functional Coupling of the Prefrontal Cortex During Working Memory in Patients with Schizophrenia

Jose A. Apud, Roberta Rasetti, Christopher Li, Qiang Chen, Xi Cheng, Jesse Hochheiser, Joseph H. Callicott, Karen F. Berman, Daniel R. Weinberger, Venkata Mattay

198. Neural Correlates of the Discrepancy between Verbal and Performance IQ

Amy Margolis, Ravi Bansal, XueJun Hao, Cole Erickson, Bradley S. Peterson

Poster Session III—Wednesday

199. Role of Hypocretin-Dynorphin Co-transmission in Motivated Behavior

John Muschamp, Jonathan Hollander, Jennifer Thompson, Sara Onvani, Linda Hassinger, Theodore Kamenecka, Stephanie Borgland, Paul Kenny, William Carlezon

200. Functional Capacity Assessment in Older Adult Populations

Sara J. Czaja, Philip D. Harvey, David Loewenstein

201. Differences in Amphetamine-evoked Dopamine Release in Cortex and Striatum

Hank P. Jedema, Rajesh Narendran, Charles W. Bradberry

202. Remission during 12 Months of Double-blind Treatment with Lurasidone vs. Quetiapine XR in Patients with Schizophrenia

Antony Loebel, Josephine Cucchiaro, Jane Xu, Jay Hsu, Kaushik Sarma, Peter Warner, Andrei Pikalov, John M. Kane

203. Antidepressant-like Effects of Buprenorphine and Kappa Receptor Antagonists in Rodent Behavioral Tests

Irwin Lucki, Gregory V. Carr, Bethany R. Brookshire, Danielle Bracco, Edgardo Falcon-Morales

204. Effect of L-Methylfolate on Core Symptoms of Major Depression from a Randomized Clinical Trial

George Papakostas, Richard C. Shelton, John Zajecka, Maurizio Fava

**Poster Session III—Wednesday**

205. BDNF Val66Met Modulates BOLD Response to Affective Instrumental Learning in Humans

Mbemba Jabbi, Brett Cropp, Tiffany Nash, Philip Kohn, Raghav Mattay, Shane Kippenhan, Bhaskar S. Kolachana, Daniel R. Weinberger, Karen F. Berman

206. Reduced Default Mode Functional Connectivity between Medial Prefrontal and Superior Temporal Gyrus Regions in Youths with Bipolar Disorder

Melissa Lopez-Larson, Deborah Yurgelun-Todd

207. Heritability and Linkage Analysis of Personality in Bipolar Disorder

Tiffany A. Greenwood, Judith Badner, William Byerley, BiGS Consortium

208. Effects of Aromatase Inhibition and Androgen Activity on Serotonin and Behavior in Male Macaques

Cynthia L. Bethea, Arubala L. Reddy, Nicola Robertson, Kristine Coleman

209. Multiple Obesity-related Genes are Associated with Antipsychotic-induced Weight Gain in Drug Naïve Pediatric Patients

Jianping Zhang, Todd Lencz, Christoph Correll, Anil Malhotra

210. Reduced Risk of Neurological Disorders in Patients Receiving Lithium Treatment

James M. Prosser, Monica L. Gilbert, Ronald R. Fieve

Poster Session III—Wednesday

211. Double-blind, Placebo-controlled Trial of Pramipexole Augmentation in Treatment-resistant Major Depressive Disorder

Maurizio Fava, Cristina Cusin, Andrew A. Nierenberg, Dan V. Iosifescu, Nadia Iovieno, A. John Rush, Roy Perlis

212. Experience Integrating Ketamine into the Healthcare System: Outpatient and Inpatient Treatment of Post-partum Depression, Suicidal Ideation and Comorbid Chronic Pain- Mood Disorders

Marlon Quinones, Nancy Diazgranados, Maxim Eckmann, Somayaji Ramamurthy, Charles Bowden, Pedro L. Delgado

213. Tissue Specific Effects of Psychological Stress on the Development of Acute Insulin Resistance

Li Li, Joseph Messina, Xiaohua Li

214. Serotonergic Modulation of Neuronal Excitability in the BNST: Effects of Chronic Alcohol

Catherine Marcinkiewicz, Nora McCall, Josh Jennings, Thomas Kash

215. A Six Month Randomized Controlled Trial of Long Acting Injectable Risperdone 50 and 100 mg in Treatment Resistant Schizophrenia

Herbert Y. Meltzer, Jean-Pierre Lindenmayer, Joseph Kwentus, D. Barrett Share, Rania M. Shebaro, Karu Jayathilake

216. A Clinical Laboratory Model of Allostasis of the Brain Reward System Diurnal Cortisol and Sleep in Recently Detoxified Opioid Dependent Patients, Normal Control Subjects & Patients Drug Free for 60-90 Days

Scott Bunce, Roger Meyer, Edward Bixler, Jonathan Harris

**Poster Session III—Wednesday**

217. Neuropeptide Y Signaling in the Bed Nucleus of the Stria Terminalis  
Regulates Binge-like Alcohol Drinking

Thomas Kash, Kristen Pleil, Emily Lowery, Todd Thiele

218. Association between Microstructural Integrity of the Frontostriatal Tracts  
and School Functions: Inattention Symptoms and Sustained Attention as  
Mediators

Susan Shur-Fen Gau, Kathleen Merikangas, Wen-Yih Isaac Tseng